miRNAs as Potential Treatment Targets and Treatment Options in Cancer

Nina Petrovic1,2, Sercan Ergun3,4

  • 1Department for Radiobiology and Molecular Genetics, Vinca Institute of Nuclear Sciences, University of Belgrade, Mike Alasa 12-14, 11000, Belgrade, Serbia. dragoninspiration@yahoo.com.

Insights

MicroRNAs (miRNAs) show promise in cancer treatment by enhancing chemotherapy and radiotherapy efficacy. These small non-coding RNAs can be manipulated for targeted delivery, potentially improving cancer therapy success.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Standard cancer therapies like chemotherapy and radiotherapy lack specificity and efficacy against solid tumors.
  • These conventional treatments can cause significant side effects, highlighting the urgent need for novel therapeutic strategies.
  • MicroRNAs (miRNAs), small non-coding RNAs, play diverse roles in cancer, acting as tumor suppressors or oncogenes.

Purpose of the Study:

  • To explore the potential of microRNAs (miRNAs) as adjuncts or standalone therapies in cancer treatment.
  • To investigate the role of miRNAs in modulating the efficacy of chemotherapy and radiotherapy.
  • To assess the feasibility of chemically modifying miRNAs for improved delivery and therapeutic application.

Main Methods:

  • Review of existing literature on miRNA functions in cancer.
  • Analysis of miRNA expression patterns in relation to chemotherapy and radiotherapy sensitivity.
  • Exploration of chemical modification strategies for miRNA delivery.

Main Results:

  • MicroRNAs (miRNAs) exhibit tumor-suppressive and oncogenic functions in various cancer models.
  • Specific miRNA expression levels correlate with sensitivity to chemotherapy and radiotherapy.
  • Chemical modifications can enhance the stability and delivery of miRNAs for therapeutic use.

Conclusions:

  • MicroRNAs (miRNAs) hold significant potential to improve the efficacy of existing cancer treatments.
  • Targeted application of miRNAs, alone or in combination with standard therapies, could enhance cancer treatment outcomes.
  • Further research into miRNA-based therapies is warranted to overcome limitations of current cancer treatments.

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.0K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.2K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
987
Anticholinesterase Agents: Poisoning and Treatment01:26

Anticholinesterase Agents: Poisoning and Treatment

Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
1.7K
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.3K